Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Bories, Pierre, Prade, Naïs, Lagarde, Stéphanie, Cabarrou, Bastien, Largeaud, Laetitia, Plenecassagnes, Julien, Luquet, Isabelle, De Mas, Véronique, Filleron, Thomas, Cassou, Manon, Sarry, Audrey, Fornecker, Luc-Matthieu, Simand, Célestine, Bertoli, Sarah, Recher, Christian, Delabesse, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7529302/
https://ncbi.nlm.nih.gov/pubmed/33001991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0238795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados